Íò»¨Í²ÄÚÓÐÒ»¶¨ÊýÁ¿µÄ²ÊÉ«²£Á§Ë鯬£¬Ë鯬·¢ÉúеÄ×éºÏ,¾Í»áÓÐÎÞÇîµÄÐÂͼ°¸ºÍл¨Ñù¡£Í¬Ñù£¬ÁܰÍÁöÄÚÒìÐÍÐÔ²»Í¬µÄÁܰÍϸ°û£¬Í¨¹ý²»Í¬µÄ·½Ê½×éºÏ±äÒ죬²úÉú²»Í¬Íâ¹Û£¬Ê¹µÃÓ볦µÀÆäËüÑ×Ö¢¡¢Ö×ÁöºÍ½áºËÐÔ²¡±äÄÑÒÔÇø·Ö¡£±¾ÎÄÒԽ᳦ÁܰÍÁöΪÀý£¬¶ÔÄÚ¾µÏ±íÏÖ½øÐлã×Ü,ÒÔÌá¸ßÄÚ¾µÒ½Ê¦Õï¶Ïˮƽ£¬¼õÉÙÁÙ´²ÎóÕï¡¢ÎóÖΡ£
ÁܰÍÁö·¢Éú×é֯ѧ»ù´¡Î¸³¦µÀð¤Ä¤ÁܰÍ×éÖ¯Ö÷ÒªÓÉÃÖÉ¢ÁܰÍ×éÖ¯ºÍÁܰÍÂËÅÝ×é³É£¬ð¤Ä¤¼äÖʺÍÉÏÆ¤ÄÚµÄÃÖÉ¢ÁܰÍ×éÖ¯ÊÇð¤Ä¤Ïà¹ØÁܰÍÁö(MALT)µÄÖ÷Òª»ù´¡£¬ÁܰÍÂËÅÝÓÉÉú»¯ÖÐÐÄ(Folliclecenter)¡¢Ì×ϸ°ûÇø(Mantlezone)ºÍ±ßÔµÇø(Marginalzone)¹¹³É£¬¿É·Ö±ð·¢ÉúÂËÅÝÐÔÁܰÍÁö(FL)¡¢Ì×ϸ°ûÁܰÍÁö(MCL)¡¢±ßÔµÇøÁܰÍÁö(MALT)¡£
´ËÍ⣬ÁܰÍÂËÅÝÄÚÍâµÄ´óBÁܰÍÑùϸ°ûÃÖÂþÔöÉú¿ÉÐγÉÒ»×éÒìÖÊÐÔÖ×Áö£¬³ÆÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö£¨Í¼1£©¡£
ͼ1賦µÀÁܰÍ×éÖ¯µÄ¹¹³É¼°ÁܰÍÁöÀ´Ô´
1.ð¤Ä¤Ïà¹ØÁܰÍ×éÖ¯ÁܰÍÁö£¨MALT£©ÆðÔ´ÓÚð¤Ä¤Ïà¹ØÁܰÍ×éÖ¯£¬Ö×ÁöÓÉСÖÁÖеÈBÁܰÍϸ°û×é³É£¬ÌØÕ÷²¡±äΪÁܰÍÉÏÆ¤²¡±äºÍÂËÅÝÖ³ÈëÏÖÏó.¾µÏ¿ɱíÏÖΪÎÞµÙ»òÑǵÙð¤Ä¤Â¡Æð»òÀ£Ññ²¡±ä£¬ÒÔǰÕßÎªÖø¡£²¡±ä³£°éÂýÐÔÑ×Ö¢(ÈçÓÄÃÅÂݸ˾ú¸ÐȾ)£¬ÁÙ´²½øÕ¹»ºÂý£¬5ÄêÉú´æÂÊԼΪ90%¡«95%£¬Ïû³ýÓÄÃÅÂݸ˾ú¸ÐȾ¿É»ñµÃ³¤ÆÚ»º½â¡£
ͼ2½á³¦¾µÏ±íÏÖ£ºA°×¹â¾µÏ£ººá½á³¦¾Ö²¿ð¤Ä¤¿ÅÁ£Ñù²»Æ½£¬Ñª¹Üȱʧ£»BNBIģʽÏ¿ɼû²¡±äÓëÖÜΧð¤Ä¤·Ö½ç£¬±íÃæ¼ûÊ÷Ö¦ÑùѪ¹ÜÍø£»CÉ«ËØÄÚ¾µÏ£ºÅçÈ÷µåëÙ×ÏÈÜÒººó£¬²¡±ä´¦ÎÞÃ÷ÏÔÉ«ËØ³Á×Å
ͼ3½á³¦¾µÏ±íÏÖ£ºAΪ䳦ϢÈâÑùð¤Ä¤Ï¡Æð£¬±íÃæ¹â»¬£»BΪֱ³¦´óСԼ3cmÆêÑùð¤Ä¤Ï¡Æð£»CÖ±³¦¿É¼û´óСԼ2.0cm¡Æð£¬±íÃæÆ½»¬£¬¿É¼û²»¹æÔòѪ¹ÜÍø¡£ÒÔÉϲ¡±äÇгýºó²¡Àí¾ù֤ʵΪMALT
ͼ4½á³¦¾µÏ±íÏÖ£ºÒÒ×´½á³¦¿É¼ûÑǵÙÐÍÏ¢ÈâÑùʵÐÔÖ×Î¾Ö²¿³Ê½á½ÚÑù£¬É«Ô󷢺졣Çгýºó²¡ÀíΪMALTÁܰÍÁö
2.ÂËÅÝÐÔÁܰÍÁö(FL)ÂËÅÝÉú·¢ÖÐÐÄBϸ°ûÀ´Ô´ÐγÉÂËÅÝ×´½á¹¹£¬ÄÚ¾µÏ³£¿É¼ûÁܰÍÂËÅÝÑù½á¹¹£¬Ò×ÎóÕïΪÁܰÍÂËÅÝÔöÉúÖ¢»òÑ×֢ϢÈ⣬ÁÙ´²Ô¤ºóºÜºÃ£¬ÉõÖÁ²»ÖÎÁƿɳ¤ÆÚ´æ»î¡£
ͼ5½á³¦¾µÏ±íÏÖ£º×î³£¼ûÀàÐÍΪɢÔÚС¡¢Ô²¡¢ÇðÕîÑù¡Æð£¬¸ß¶ÈСÓÚ1mm£¬³£ÓëÁܰÍÂËÅÝÑùÔöÉú¼ø±ðÀ§ÄÑ
ͼ6¾µÏ±íÏÖ£º³ÊÏ¢ÈâÑù±íÏÖµÄÂËÅÝÐÔÁܰÍÁö£¬´óС²»µÈ£¬½ÏСÕߣ¨A-C£©ÀàËÆÎÞµÙÏÙÁöÑùÏ¢È⣬½Ï´óÕߣ¨D£©Ïñð¤Ä¤ÏÂÖ×ÁöÑù½á¹¹
ͼ7¾µÏ±íÏÖ£º³Ê±âƽ¡ÆðÐͱíÏÖµÄÂËÅÝÐÔÁܰÍÁö¡£»ýÔÆÑù»òÅÆØÒÑù£¬ÐÎ̬²»¾ùÒ»µÄð¤Ä¤Â¡Æð
3.Ì×ϸ°ûÁܰÍÁö£¨MCL£©Ð¡Bϸ°û·Ç»ôÆä½ðÁÜÖаÍÁö£¨NHL£©µÄÒ»ÖÖ£¬ÓÉÐÎ̬µ¥Ò»µÄСÖÁÖеȴóСµÄÁܰÍÑùϸ°û¹¹³É£¬Ï¸°ûºË²»¹æÔò£¬ÀàËÆÓÚÖÐÐÄϸ°û/ÓÐÁÑÂËÅÝÖÐÐÄϸ°û¡£Î¸³¦µÀ±íÏÖΪ¶à·¢ÁܰÍÁöÑùÏ¢Èⲡ£¬Ö±¾¶0.5-2.0cm,Òà¿ÉΪ¹ÂÁ¢Ö׿顣»¯ÁÆ¿ÉÒÔ²¿·Ö»òÍêÈ«»º½â£¬µ«¸´·¢³£¼û£¬5Äê´æ»îÂÊÔ¼50%.
ͼ8Ì×ϸ°ûÁܰÍÁö¾µÏ±íÏÖ£º¿É¼û¶à·¢Ï¢ÈâÑùð¤Ä¤Ï¡Æð£¬ÀàËÆÆÌ·ʯÑù¸Ä±ä¡£A£ºÉý½á³¦£»B:ºá½á³¦£»C£ºÖ±³¦
ͼ9Ì×ϸ°ûÁܰÍÁö¾µÏ±íÏÖ£ºÈ«½á³¦É¢ÔÚÎÞµÙÏ¢ÈâÑùð¤Ä¤Ï¡Æð¡£A°×¹âÏÂÔ¶¾°£»BI-SCANģʽ£»C°×¹âϽü¾°
ͼ10Ì×ϸ°ûÁܰÍÁöÔÚͬһ²¡È˳¦µÀÖУ¬¼´¿É±íÏֶ෢ϢÈâÐÍ(A)£¬Ò²¿É±íÏÖΪ¹ÂÁ¢Ö׿éÐÍ(B)
4.ÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö(DLBCL)ÃÖÂþ´óBϸ°ûÁܰͶàΪÇÖÏ®ÐÔ·Ç»ôÆæ½ðÁܰÍÁö£¬Ò²ÊÇ賦µÀ¶ñÐÔÁܰÍÁö×î³£¼ûÀàÐÍ,¶Ô»¯ÁÆÃô¸Ð£¬°ëÊý¿ÉÍêÈ«»º½â¡£CHOP+CD2µ¥¿¹¿É¸ÄÉÆÉú´æÆÚ¡£ÈôÓÐÒÔϾµÏ±íÏÖ£¬Ó¦¼ÓÒÔ»³ÒÉ£º¢Ù¶à·¢¡¢Ç³±íµØÍ¼×´À£Ññ£¬±ß½ç²»Çå»ò±ßԵ¡ÆðÔöºñ£»¢Ú»ØÃ¤²¿¡¢»Ø³¦Ä©¶ËµÄ²»Ã÷ÔÒòµÄð¤Ä¤ÃÓÀá¢À£Ññ¼°¶à·¢ÐÔÏ¢ÈâÑù¸Ä±ä£»¢Ûð¤Ä¤ÖåôÅÔö´ÖËÆÄÔ»Ø×´¡£
ͼ11¾µÏ±íÏÖ£º¼´¿É±íÏÖΪA-BµÄÖ׿éÐÍ£¬Ò²¿ÉΪCµÄÀ£ÑñÐÍ£¬DµÄ½þÈóÐÍ
5.³¦²¡Ïà¹ØTϸ°ûÁܰÍÁö£¨EATL)Ô·¢ÓÚ³¦µÀµÄ¿ÉÄÜÀ´Ô´ÓÚ³¦µÀÉÏÆ¤ÄÚTÁܰÍϸ°ûµÄ½áÍâTϸ°ûÁܰÍÁö,³£¼ûÓڿջس¦£¬ÉÙ¼ûÓÚС³¦£¬³Ê½Ú¶ÎÐÔ·Ö²¼£¬±íÏÖΪ¶àÔîÐÔ²»¹æÔòÀ£Ññ£¬Ó볦½áºË¡¢¿ËÂÞ¶÷²¡¡¢³¦ÐͰ×Èû²¡¡¢½á³¦°©µÈ²¡±äÄÑÒÔÇø·Ö¡£Tϸ°ûÁܰÍÁö±ÈBϸ°ûÁܰÍÁöÉÙ¼û£¬ÁÙ´²½ÏÄÑÕï¶Ï¡£´ó²¿·ÖÔÚ·¢ÏÖʱ£¬ÒÑ´¦ÓÚ½øÕ¹ÆÚ£¬1ÄêºÍ5ÄêÉú´æÂÊ·Ö±ðΪ31%~39%ºÍ8%~20%¡£
ͼ12½á³¦¾µÏ±íÏÖ£ºA»Ø³¦Î´¶Ëð¤Ä¤¸ß¶È³äѪˮÖ×£¬±íÃæ³ÊÂíÈü¿ËÑù£¬»ØÃ¤°ê¿ª´ó¡¢±äÐΣ»BÉý½á³¦½ü»ØÃ¤²¿¿É¼ûÀ£ÑñÐÔÖ׿飻C½µ½á³¦¿É¼û²»Á¬Ðø´©ÔäÑùÀ£Ññ£¬³¦¹Ü±ÚÔöºñ£»DÊÖÊõÇгýºó´óÌå±ê±¾
ͼ13Tϸ°û½á³¦¾µÏ±íÏÖ£ºÈ«³¦µÀ¼û¶à·¢¡¢Éî´ó¡¢µØÍ¼ÑùÀ£Ññ£¬±íÃæ¸²Ñ×ÐÔÉø³öÎÖÜΧð¤Ä¤ÒòË®Ö×¶ø³Ê¡ÆðÑù¸Ä±ä
С½áθºÍ³¦µÀ¶¼ÊǸ»º¬ÁܰÍÑù×éÖ¯µÄ·ÇÁÜ°ÍÆ÷¹Ù£¬¶¼ÊǽáÍâÁܰÍÁöµÄºÃ·¢²¿Î»£¬µ«ÓëÆäËû¶ñÐÔÖ×ÁöÏà±È£¬ÈÔÊÇÉÙ¼û²¡£¬³¦µÀÁܰÍÁöµÄÁÙ´²±íÏÖ¶àÑù»¯£¬È±·¦ÌØÒìÐÔ£¬Ö×Áöϸ°ûÔÚð¤Ä¤ÏÂÉú³¤£¬»î¼ìÈ¡²ÄÀ§ÄÑ£¬Â©ÕïºÍÎóÕïÂʸߣ¬Òò´Ë¼ÓÇ¿ÁÙ´²Ò½Éú¶Ô³¦µÀÁܰÍÁöµÄÈÏʶÊǼõÉÙÎó©ÕïµÄµÚÒ»²½¡£
¶ÔÓÚÁÙ´²ÉϵIJ»µäÐ͵ÄÀ£Ññ¡¢Ï¢Èâ¡¢Ö׿éÑù²¡±ä£¬Èç±ßÔµÈñÀû£¬À£ÑñÅÔð¤Ä¤È±·¦Ã÷ÏÔÑ×·´Ó¦µÄ²¡±ä£¬Òª¿¼Âǵ½´Ë²¡µÄ¿ÉÄÜÐÔ¡£±ØÒªÊ±´ó¿é»î¼ì¡¢ËíµÀʽ»î¼ìÉõÖÁÊÖÊõÇгý£¬ÒÔÃ÷È·²¡Òò¡£
±¾ÎÄ×÷ÕߣºÒ½ÔºÏû»¯¿ÆÎâÎÄÃ÷κ־
±à¼£ºÕÅÔ¾Ææ
»Ø¸´Î¸³¦£¬¼´¿ÉÏÂÔØ¡¶Î¸¾µ¼ì²éÊõ¡·ºÍ¡¶½á³¦¾µµ¥È˲Ù×÷Óë¼¼ÇÉ¡·¡£²Î¿¼ÎÄÏ×
[1]SeoSW,LeeSH,LeeDJ,etal.Colonicmucosa-associatedlymphoidtissuelymphomaidentifiedbychromoendoscopy[J].WorldJGastroenterol,,20(48):-.
[2]AkasakaR,ChibaT,DuttaAK,etal.Colonicmucosa-associatedlymphoidtissuelymphoma[J].CaseRepGastroenterol,,6(2):-.
[3]KimMH,JungJT,KimEJ,etal.Acaseofmucosa-associatedlymphoidtissuelymphomaofthesigmoidcolonpresentingasasemipedunculatedpolyp[J].ClinEndosc,,47(2):-.
[4]IwamuroM,OkadaH,TakataK,etal.ColorectalManifestationofFollicularLymphoma[J].InternMed,,55(1):1-8.
[5]ÀîΡÕÅ.½á³¦Ì×ϸ°ûÁܰÍÁö1Àý[J].賦²¡Ñ§ºÍ¸Î²¡Ñ§ÔÓÖ¾,,12:.
[6]BouwensMW,MascleeAA,SanduleanuS.Colonicmantlecelllymphoma[J].ClinGastroenterolHepatol,,10(3):e25-26.
[7]NetoAG,OrosziG,ProtivaP,etal.Colonicinsitumantlecelllymphoma[J].AnnDiagnPathol,,16(6):-.
[8]Þ±£¬ÕÅÑÇÀúÖì.ÈçºÎͨ¹ýÄÚ¾µ»î¼ìÌá¸ß´ó³¦ÁܰÍÁöµÄÕï¶Ïˮƽ[J].賦²¡Ñ§ºÍ¸Î²¡Ñ§ÔÓÖ¾,,21(2):-.
[9]ZhangJC,WangY,WangXF,etal.TypeIenteropathy-associatedT-celllymphomainthecolonofa29-year-oldpatientandabriefliteraturereview[J].OncoTargetsTher,,9:-.
ÔÞÉÍ
³¤°´å“ªé‡Œæ²»ç™½ç™œé£Žæœ€ä¸“业北京治疗白癜风有哪些方法
×ªÔØÇë×¢Ã÷£ºhttp://www.yueyangmaoyi.net/jbgs/29.html